F058 New Drugs, New Rashes: An Update on Cutaneous Drug Eruptions
DESCRIPTION
Adverse drug reactions are inevitable sequelae of contemporary medical management and mucocutaneous eruptions rank among the most common of these reactions. Newer medications with significant drug eruption rates, and serious or characteristic cutaneous effects include newer cancer therapies and biologics. It is a challenge for the practicing dermatologist to stay abreast of these new drugs and new rashes. Additionally, knowledge and management of severe drug eruptions in constantly evolving. This session will provide a comprehensive update on drug eruptions and their management.
LEARNING OBJECTIVES
Diagnose and manage dermatologic adverse events with novel cancer therapies, including immune checkpoint inhibitors and targeted therapies.
Recognize and manage cutaneous side effects of biologic therapies
SCHEDULE
3:30 PM
Dermatologic adverse events with immune checkpoint inhibitors
Jennifer N. Choi, MD, FAAD
3:55 PM
Dermatologic adverse events with novel targeted therapies
Lauren Marie Guggina, MD, FAAD
4:20 PM
Q&A
Jennifer N. Choi, MD, FAAD, Lauren Marie Guggina, MD, FAAD
4:30 PM
Controversies in Severe Cutaneous Adverse Reactions
Benjamin Kaffenberger, MD, MS, FAAD
4:55 PM
Cutaneous side effects of biologic therapies
William Damsky, PhD, MD, FAAD
5:20 PM
Q&A
William Damsky, PhD, MD, FAAD, Benjamin Kaffenberger, MD, MS, FAAD
DIRECTOR
Connie Shi, MD, FAAD
Brigham and Women's Hospital, Department of Dermatology; Dana Farber Cancer Institute, Division of Cutaneous Oncology
SPEAKERS
Jennifer N. Choi, MD, FAAD
William Damsky, PhD, MD, FAAD
Lauren Marie Guggina, MD, FAAD
Mass General Brigham and Dana-Farber Cancer Institute
Benjamin Kaffenberger, MD, MS, FAAD
Ohio State university
DISCLOSURES
Jennifer N. Choi, MD, FAAD
CeraVe/Valeante – Independent Contractor(Fees); Janssen Global Services, LLC – Advisory Board(Fees); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Fees); OnQuality Pharmaceuticals, Ltd. – Advisory Board(Fees); PraHealth Sciences – Advisory Board(Fees); Pyxis Oncology – Advisory Board(Fees); Regeneron Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees);
William Damsky, PhD, MD, FAAD
AbbVie – Investigator(Fees); Advanced Cell Diagnostics, Inc. – Investigator(Equipment); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); CSL Behring – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Fees); Epiarx Diagnostics – Consultant (1099 relationship)(Fees); Fresenius Kabi – Consultant (1099 relationship)(Fees); Incite – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); MilliporeSigma – Other(Patent royalties or other compensation for Intellectual Property Rights); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); TWi Biote – Consultant (1099 relationship)(Fees); TWi Biotechnology, Inc. – Consultant(Fees), Consultant (1099 relationship)(Fees), Investigator(Fees);
Lauren Marie Guggina, MD, FAAD
SynOx Therapeutics – Consultant (1099 relationship)(Fees), Data Safety Monitoring Board(Fees);
Benjamin Kaffenberger, MD, MS, FAAD
Almirall – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant (1099 relationship)(Honoraria); HCW Biologics – Investigator(Grants/Research Funding); InflaRx – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Leo Pharma – Investigator(Grants/Research Funding); National Comprehensive Cancer Network – Speaker(Honoraria); Pfizer Inc. – Data Safety Monitoring Board(Fees); Protillion Biosciences – Consultant (1099 relationship)(Stock Options);
Connie Shi, MD, FAAD
No financial relationships exist with ineligible companies.